1. Home
  2. MHO vs NAMS Comparison

MHO vs NAMS Comparison

Compare MHO & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MHO

M/I Homes Inc.

HOLD

Current Price

$126.48

Market Cap

3.3B

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$34.73

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MHO
NAMS
Founded
1976
2019
Country
United States
Netherlands
Employees
N/A
100
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3B
3.5B
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
MHO
NAMS
Price
$126.48
$34.73
Analyst Decision
Buy
Strong Buy
Analyst Count
3
8
Target Price
$160.00
$46.75
AVG Volume (30 Days)
178.6K
809.9K
Earning Date
04-22-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
14.74
N/A
Revenue
$4,417,781,000.00
N/A
Revenue This Year
$0.66
$17.96
Revenue Next Year
$6.97
$540.65
P/E Ratio
$8.10
N/A
Revenue Growth
N/A
N/A
52 Week Low
$102.44
$15.82
52 Week High
$158.92
$42.00

Technical Indicators

Market Signals
Indicator
MHO
NAMS
Relative Strength Index (RSI) 51.72 57.13
Support Level $125.38 $34.05
Resistance Level $127.81 $37.43
Average True Range (ATR) 3.66 1.75
MACD 0.75 0.19
Stochastic Oscillator 86.73 74.13

Price Performance

Historical Comparison
MHO
NAMS

About MHO M/I Homes Inc.

M/I Homes Inc is an American construction company that focuses on residential construction. It consists of two distinct operations: homebuilding and financial services. The homebuilding operations are spread into the Midwest, Mid-Atlantic, and Southern regions, and the financial services operations support homebuilding operations by providing mortgage loans and title services to the customers of homebuilding operations. Homebuilding operations comprises a predominant portion of the revenue. The company builds homes and communities that target entry-level, move-up, and luxury homebuyers.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: